<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343157">
  <stage>Registered</stage>
  <submitdate>5/07/2011</submitdate>
  <approvaldate>12/07/2011</approvaldate>
  <actrnumber>ACTRN12611000721909</actrnumber>
  <trial_identification>
    <studytitle>Sulodexide effect on walking ability in patients with intermittent claudication</studytitle>
    <scientifictitle>Sulodexide effect on intermittent claudication in patients presenting Fontaine stage II peripheral arterial occlusive disease</scientifictitle>
    <utrn>U1111-1122-6394</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Intermittent claudication</healthcondition>
    <healthcondition>Peripheral arterial occlusive disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>sulodexide at the dose of 100 mg daily (two 25 mg capsules twice a day) for a period of one month.</interventions>
    <comparator>placebo: two sugar pills capsules twice a day for a period of one month.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Initial claudication distance ratio (ICDr), defined as the ratio of post-treatment to pre-treatment pain-free walking distance tolerated by the patient</outcome>
      <timepoint>at one month</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral hemodynamics changes measured by ankle brachial index</outcome>
      <timepoint>at one month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective evaluation of the walking impairment (walking impairment questionnaire)</outcome>
      <timepoint>at one month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>-	Subjective evaluation of the quality of life expressed on an arbitrary score:
0: absence of subjective symptoms (pain, cramps, numbness, burning sensation, fatigue)
1: tolerable subjective symptoms not interfering with daily life activities 
2: moderate subjective symptoms limiting daily activities
3: severe and disabling subjective symptoms</outcome>
      <timepoint>at one month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-	Typical intermittent claudication confirmed by a reduced ankle brachial index (0.7 on the worst leg measured by a Doppler probe) 
-	A maximum initial walking distance between 30 and 500 m measured by a treadmill test
-	A maximum change in initial walking distance inferior to 25% on two treadmill tests performed before the inclusion of the patients 
-	Stability of the patient conditions for the last month</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-	An acute deterioration of the patient condition in the last month.
-	High variability in walking distances, 
-	Illness limiting the exercise capacity: uncontrolled hypertension, angina pectoris, unstable angina, severe cardiac conduction abnormalities, uncontrolled congestive heart failure, respiratory diseases, orthopedic diseases, neurological disorders
-	History of hypersensitivity to extractive mucopolysaccharides
-	Severe hemodynamic stenosis of pelvic arteries
-	Inflammatory vascular diseases (e.g. thromboangeitis, immunoangiopathy, vascular and collagen disorders);
-	Aneurysm of the abdominal aorta</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/08/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Georges Tabet</primarysponsorname>
    <primarysponsoraddress>Hotel Dieu de France Hospital
Alfred Naccache Street
Achrafieh, Beirut</primarysponsoraddress>
    <primarysponsorcountry>Lebanon</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Georges Tabet</fundingname>
      <fundingaddress>Hotel Dieu de France Hospital
Alfred Naccache Street
Achrafieh, Beirut</fundingaddress>
      <fundingcountry>Lebanon</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Sulodexide, a standardized extractive glycosaminoglycans, was recently implicated in the treatment of intermittent claudication. In this current study, we plan to conduct a randomized double blind placebo control study for a period of one month in patients with Fontaine stage II peripheral arterial occlusive disease.  This study will cover the effects of sulodexide on walking performance, ankle brachial index and quality of life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethical committee of Hotel Dieu de France Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Lebanon</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Georges Tabet</name>
      <address>Hotel Dieu de France Hospital
Alfred Naccache Street
Achrafieh, Beirut</address>
      <phone>+961 1 612662</phone>
      <fax>+961 1 612663</fax>
      <email>lamisse.karam@gmail.com</email>
      <country>Lebanon</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georges Tabet</name>
      <address>Hotel Dieu de France Hospital
Alfred Naccache Street
Achrafieh, Beirut</address>
      <phone>+961 1 612662</phone>
      <fax />
      <email>lamisse.karam@gmail.com</email>
      <country>Lebanon</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georges Tabet</name>
      <address>Hotel Dieu de France Hospital
Alfred Naccache Street
Achrafieh, Beirut</address>
      <phone>+961 1 612662</phone>
      <fax>+961 1 612663</fax>
      <email>lamisse.karam@gmail.com</email>
      <country>Lebanon</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>